ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Italy’s Dipharma will acquire Kalexsyn

by Michael McCoy
April 29, 2018 | APPEARED IN VOLUME 96, ISSUE 18

The Italian pharmaceutical chemical maker Dipharma has struck a deal to acquire Kalexsyn, a Kalamazoo, Mich.-based provider of contract research services. Dipharma says the purchase will mesh Kalexsyn’s ability to carry out difficult syntheses of molecules for preclinical drug studies with its commercial manufacturing skills. Dipharma plans to install equipment allowing Kalexsyn to make larger volumes of molecules for clinical trials. Kalexsyn was formed in 2003 by two former Pfizer chemists.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment